drugset / Trial / NCT04060030

Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism

NCT04060030

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the cognitive and behavioral effects of liquid leucovorin calcium on young children with autism spectrum disorder (ASD) and determine whether it improves social communication as well as the core and associated symptoms of ASD. The investigators will enroll 80 children across two sites, between the ages of 2.5 and 5 years, with confirmed ASD and known social and communication delays. Participation will last approximately 26 weeks, from screening visit to end of treatment.

Timeline

Start
2020-10-08
Primary completion
2026-07-31
Completion
2026-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Levoleucovorin Unknown 1 mg/kg